Episode # 3 • 17 Jan 2025
Managing Refractory MSS-MCRC: Advanced Treatment Strategies
What options remain when a patient with microsatellite stable metastatic colorectal cancer (MSS mCRC) has progressed through every standard line of chemotherapy? On this episode of BackTable Tumor Board, Dr. Jun Gong is joined by Dr. Ibrahim Sahin and Dr. Sandra Algaze to explore the nuances of late-line management in MSS-mCRC. They discuss how to approach oxaliplatin retreatment and anti-EGFR rechallenge, the growing role of liquid biopsy and biomarker-driven selection, and the practicalities of DPYD testing after recent guideline changes.
Timestamps
00:00 - Introduction
01:55 - Oxaliplatin Retreatment and Anti-EGFR Rechallenge
07:53 - DPYD Testing and Liquid Biopsy
14:00 - Comparing Rechallenge and Conventional Agents
15:42 - STELLAR-303 and Third-Line Options
22:53 - Immunotherapy and MSS Biology
25:42 - SUNLIGHT, FRESCO-2, and CORRECT Trials
30:41 - Alternative Dosing Strategies
32:02 - Botensilimab and Balstilimab Update
37:06 - Neoadjuvant Immunotherapy
38:15 - Emerging Antibody-Drug Conjugates
42:02 - Closing Remarks
Resources
You may also like
More about this episode
The conversation walks through the latest clinical trial results for third-line and beyond, including strategies for dosing and tolerability, and the unique challenges posed by liver metastases. Drs. Sahin and Algaze highlight new developments in immunotherapy, antibody-drug conjugates, and bispecific antibodies, as well as the importance of matching therapy to both tumor biology and patient needs. They close with insights on patient monitoring, toxicity management, and the value of multidisciplinary care for this complex population.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.